Cellular stress induces non-canonical activation of the receptor tyrosine kinase EphA2 through the p38-MK2-RSK signaling pathway
Journal of Biological Chemistry · 2023
DOI: 10.1016/j.jbc.2023.104699 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2023. Verfasst von Yue Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama; Toyama, Japan. Hauptthemen laut MEDLINE: Glioblastoma, Receptor, EphA2, Signal Transduction. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research Institute, Kanazawa University, Kanazawa University, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
The receptor tyrosine kinase ephrin type-A receptor 2 (EphA2) is overexpressed in malignant tumors. We previously reported that non-canonical EphA2 phosphorylation at Ser-897 was catalyzed by p90 ribosomal S6 kinase (RSK) via the MEK-ERK pathway in ligand- and tyrosine kinase-independent manners. Non-canonical EphA2 activation plays a key role in tumor progression; however, its activation mechanism remains unclear. In the present study, we focused on cellular stress signaling as a novel inducer of non-canonical EphA2 activation. p38, instead of ERK in the case of epidermal growth factor signaling, activated RSK-EphA2 under cellular stress conditions, including anisomycin, cisplatin, and high osmotic stress. Notably, p38 activated the RSK-EphA2 axis via downstream MAPK-activated protein kinase 2 (MK2). Furthermore, MK2 directly phosphorylated both RSK1 Ser-380 and RSK2 Ser-386, critical residues for the activation of their N-terminal kinases, which is consistent with the result showing that the C-terminal kinase domain of RSK1 was dispensable for MK2-mediated EphA2 phosphorylation. Moreover, the p38-MK2-RSK-EphA2 axis promoted glioblastoma cell migration induced by temozolomide, a chemotherapeutic agent for the treatment of glioblastoma patients. Collectively, the present results reveal a novel molecular mechanism for non-canonical EphA2 activation under stress conditions in the tumor microenvironment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama; Toyama, Japan.
- Department of Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan; Division of Medical Oncology, Cancer Research Institute, Kanazawa…
- Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama; Toyama, Japan. Electronic address: hsakurai@pha.u-toyama.ac.jp.
Förderung
- Cancer Research Institute, Kanazawa University
- Kanazawa University
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
- MSD Life Science Foundation, Public Interest Incorporated Foundation
- MSD Kabushiki Kaisha
Zitieren
APA
Zhou, Y., Oki, R., Tanaka, A., Song, L., Takashima, A., Hamada, N., Yokoyama, S., Yano, S., & Sakurai, H. (2023). Cellular stress induces non-canonical activation of the receptor tyrosine kinase EphA2 through the p38-MK2-RSK signaling pathway. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2023.104699
Vancouver
Zhou Y, Oki R, Tanaka A, Song L, Takashima A, Hamada N, et al. Cellular stress induces non-canonical activation of the receptor tyrosine kinase EphA2 through the p38-MK2-RSK signaling pathway. Journal of Biological Chemistry. 2023. doi:10.1016/j.jbc.2023.104699
BibTeX
@article{Zhou2023,
author = {Zhou, Yue and Oki, Ryota and Tanaka, Akihiro and Song, Leixin and Takashima, Atsushi and Hamada, Naru and Yokoyama, Satoru and Yano, Seiji and Sakurai, Hiroaki},
title = {Cellular stress induces non-canonical activation of the receptor tyrosine kinase EphA2 through the p38-MK2-RSK signaling pathway},
journal = {Journal of Biological Chemistry},
year = {2023},
doi = {10.1016/j.jbc.2023.104699}
}
EUVIMED